Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Ascletis Pharma Inc / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ascletis-pharma-inc" target="_blank" data-smartkarma-citation="entities:27265:1" rel="noopener">Ascletis Pharma Inc (1672 HK)</a> announced the placement of 52.4M shares for subscription at HK$16.45 per share.</li>
<li>The company intends to use 90% of proceeds for further R&amp;D of its drug candidates with respect to both subcutaneously injected peptides and oral peptides, into clinical trials for obesity.</li>
<li>The company will take time to cash in fully from the commercialization efforts in near future, given the limited opportunity it has in terms of the drug pipeline basket.</li>
</ul>



Ascletis Pharma Inc (1672 HK) announced the placement of 52.4M shares for subscription at HK$16.45 per share.
The company intends to use 90% of proceeds for further R&amp;D of its drug candidates with respect to both subcutaneously injected peptides and oral peptides, into clinical trials for obesity.
The company will take time to cash in fully from the commercialization efforts in near future, given the limited opportunity it has in terms of the drug pipeline basket.


Guangzhou Innogen Pharmaceutical Group (2591 HK)

Ascletis Pharma (1672 HK): Placement Bleak; Commercialization To Take Time; Lack Formidable Pipeline